Abbott Laboratories provided earnings guidance for 2021. For the year, the company expects diluted EPS from continuing operations on a GAAP basis of at least $3.74 and full-year adjusted diluted EPS from continuing operations of at least $5.00, reflecting growth of more than 35% versus the prior year. Full year 2021 guidance for diluted EPS from continuing operations on a GAAP basis reflects growth of at least 50% versus the prior year.